Bupivacaine Accord 5 mg/ ml Norge - norsk - Statens legemiddelverk

bupivacaine accord 5 mg/ ml

accord healthcare b.v. - bupivakainhydroklorid - injeksjonsvæske, oppløsning - 5 mg/ ml

Bupivacaine Accord 2.5 mg/ ml Norge - norsk - Statens legemiddelverk

bupivacaine accord 2.5 mg/ ml

accord healthcare b.v. - bupivakainhydroklorid - injeksjonsvæske, oppløsning - 2.5 mg/ ml

Letrozol Accord 2.5 mg Norge - norsk - Statens legemiddelverk

letrozol accord 2.5 mg

accord healthcare b.v. - letrozol - tablett, filmdrasjert - 2.5 mg

Docetaxel Actavis 20 mg/ ml Norge - norsk - Statens legemiddelverk

docetaxel actavis 20 mg/ ml

actavis group ptc ehf - docetaksel - konsentrat til infusjonsvæske - 20 mg/ ml

Sitagliptin Accord Den europeiske union - norsk - EMA (European Medicines Agency)

sitagliptin accord

accord healthcare s.l.u. - sitagliptin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus, sitagliptin accord is indicated to improve glycaemic control:as monotherapy:- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. as dual oral therapy in combination with:- metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control. - a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance. - a peroxisome proliferator-activated receptor gamma (ppary) agonist (i. a thiazolidinedione) when use of a ppary agonist is appropriate and when diet and exercise plus the ppary agonist alone do not provide adequate glycaemic control. as triple oral therapy in combination with:- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. - a ppary agonist and metformin when use of a ppary agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. sitagliptin accord is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.

Neurolite - Norge - norsk - Statens legemiddelverk

neurolite -

lantheus mi uk ltd. - bicisatdihydroklorid ad tc-99m bicisate - pulver og væske til injeksjonsvæske, oppløsning

Steripet 250 MBq/ ml Norge - norsk - Statens legemiddelverk

steripet 250 mbq/ ml

ge healthcare b.v. - fludeoksyglukose (18f) - injeksjonsvæske, oppløsning - 250 mbq/ ml

Ceretec - Norge - norsk - Statens legemiddelverk

ceretec -

ge healthcare as - eksametazim - preparasjonssett til radioaktive legemidler

Drytec TM - Norge - norsk - Statens legemiddelverk

drytec tm -

ge healthcare b.v. - natriummolybdat mo-99 omdannes til natriumperteknetat tc-99m - radionuklidegenerator

Nanocoll - Norge - norsk - Statens legemiddelverk

nanocoll -

ge healthcare as - albumin humant kolloidale partikler ad tc-99m albumin nanokolloid - pulver til injeksjonsvæske, suspensjon